ASH 2018: MRD in Relapse

2019 Multiple Myeloma Symposium | Novel and Next Generation TherapyПодробнее

Bruno Paiva | ASH 2018 | The role of MRD in redefining CR in elderly patients with AMLПодробнее

Koichi Takahashi | ASH 2018 | Clonal heterogeneity of AML and its evolution at relapseПодробнее

Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer InstituteПодробнее

Bruno Paiva | ASH 2018 | The clinical significance of MRD for high-risk multiple myelomaПодробнее

What impact does MRD status have on the outcomes of patients with AML undergoing allo-SCT?Подробнее

Marc-Andrea Baertsch | ASH 2018 | Update on the results of the ReLapsE trialПодробнее

Identifying relapse in B-ALL patients treated with tisagenlecleucel using MRDПодробнее

ASH 2018: Blood MonitoringПодробнее

MRD Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma PatientsПодробнее

How can serial MRD monitoring be utilized to improve relapse outcomes?Подробнее

The Myeloma Summary Post ASH 2018Подробнее

ASH 2019 updates on Minimal Residual Disease (MRD) - ItalianПодробнее

Phase II study shows blinatumomab achieves minimal residual disease response in ALLПодробнее

Myeloma XI trial: impact of MRD on treatment response in MMПодробнее

Musa Yilmaz | ASCO 2018 | Can relapse occur in AML patients after a long period of remission?Подробнее

Best of ASH 2018Подробнее

ASH 2018: MaintenanceПодробнее

MRD to determine risk of relapse after induction in AMLПодробнее

ASH 2018: Frontline TherapyПодробнее

Game-Changing Potential of MRD in Hematological Malignancies: Overview and ImportanceПодробнее